PE44997A1 - Formulacion oral de 2-metil-tieno-benzodiacepina (olanzapina) y procedimiento de preparacion - Google Patents
Formulacion oral de 2-metil-tieno-benzodiacepina (olanzapina) y procedimiento de preparacionInfo
- Publication number
- PE44997A1 PE44997A1 PE1996000204A PE00020496A PE44997A1 PE 44997 A1 PE44997 A1 PE 44997A1 PE 1996000204 A PE1996000204 A PE 1996000204A PE 00020496 A PE00020496 A PE 00020496A PE 44997 A1 PE44997 A1 PE 44997A1
- Authority
- PE
- Peru
- Prior art keywords
- olanzapine
- oral formulation
- hydroxypropilcellulose
- refers
- benzodiacepine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract 1
- 229960005017 olanzapine Drugs 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
SE REFIERE A UNA COMPOSICION ANTIPSICOTICA, DONDE: EL PRINCIPIO ACTIVO ES LA FORMA POLIMORFICA ALTAMENTE PURA DE OLANZAPINA DE 1% A 3% P/P, CARACTERIZADO POR VALORES DE ESPACIOS INTERPLANARES DE 10,2689A� A 2,6007A� APROXIMADAMENTE; EL AGENTE DE CARGA ES LACTOSA DE 69,5% A 87,5% P/P, EL AGLUTINANTE ES HIDROXIPROPILCELULOSA DE 3,5 A 4,5% P/P, EL DISGREGANTE ES CROSPOVIDONA DE 4% A 6% P/P, EL AGLUTINANTE SECO ES CELULOSA MICROCRISTALINA DE 9% A 11%; EL LUBRICANTE ES ESTEARATO DE MAGNESIO DE 0,25% A 1%; EN LA RECUBIERTA AL POLIMERO SELECCIONADO ENTRE HIPROMELOSA, HIDROXIPROPILCELULOSA Y ETILCELULOSA, ENTRE OTROS, MAS PREFERIBLEMENTE HIDROXIPROPILHIPROMELOSA; EN EL SOBRECUBRIMIENTO AL HIDROXIPROPILHIPROMELOSA RECUBIERTO ADICIONALMENTE CON UNA PELICULA EN DISPERSION ACUOSA. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE UNA FORMULACION ORAL SOLIDA, QUE COMPRENDE LA GRANULACION HUMEDA ACUOSA DE ALTA CIZALLA Y EL SECADO EN LECHO FLUIDO. ESTA FORMULACION NO PERMITE EL CAMBIO DE COLOR FARMACEUTICAMENTE NO ACEPTABLE, BAJO CONDICIONES DE ALMACENAMIENTO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41046595A | 1995-03-24 | 1995-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE44997A1 true PE44997A1 (es) | 1997-10-23 |
Family
ID=23624847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1996000204A PE44997A1 (es) | 1995-03-24 | 1996-03-22 | Formulacion oral de 2-metil-tieno-benzodiacepina (olanzapina) y procedimiento de preparacion |
Country Status (46)
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR5278A (es) * | 1995-03-24 | 1996-07-04 | Lilly Co Eli | Formulacion oral de 2-metil-tieno-benzodiacepina |
ID21762A (id) * | 1996-09-24 | 1999-07-22 | Lilly Co Eli | Formulasi partikel bersaput |
US20020035071A1 (en) * | 1997-07-08 | 2002-03-21 | Josef Pitha | Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites |
US8563522B2 (en) * | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
US20060116330A1 (en) * | 1997-07-08 | 2006-06-01 | The Iams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
AU779452B2 (en) * | 1999-12-28 | 2005-01-27 | Cipla Limited | New polymorphic forms of olanzapine |
US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
US6348458B1 (en) | 1999-12-28 | 2002-02-19 | U & I Pharmaceuticals Ltd. | Polymorphic forms of olanzapine |
US6740753B2 (en) | 2001-01-04 | 2004-05-25 | Geneva Pharmaceuticals, Inc. | Olanzapine crystal modification |
US20030072731A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing starch or dextrin |
US20030072729A1 (en) * | 2001-05-15 | 2003-04-17 | Christopher Szymczak | Simethicone as weight gain enhancer |
US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
GB0203061D0 (en) * | 2002-02-08 | 2002-03-27 | Novartis Ag | Organic compounds |
EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
AU2002255196A1 (en) * | 2002-04-18 | 2003-10-27 | Dr. Reddy's Laboratories Ltd. | Rapidly dispersing solid oral compositions |
AU2003237305A1 (en) | 2002-05-31 | 2003-12-19 | Geneva Pharmaceuticals, Inc. | Process of preparation of olanzapine form i |
SI21270A (sl) * | 2002-07-15 | 2004-02-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kristalne oblike olanzapina in postopki za njihovo pripravo |
US7029112B2 (en) * | 2002-08-05 | 2006-04-18 | Mars, Incorporated | Ink-jet printing on surface modified edibles and products made |
US8168170B2 (en) * | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
PL202856B1 (pl) * | 2002-12-20 | 2009-07-31 | Adamed Spo & Lstrok Ka Z Ogran | Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny |
WO2005009407A2 (en) * | 2003-07-29 | 2005-02-03 | Ranbaxy Laboratories Limited | Oral pharmaceutical formulations of olanzapine |
WO2005034921A1 (en) * | 2003-10-07 | 2005-04-21 | Andrx Pharmaceuticals Llc | Rapidly disintegrating formulation |
CA2546200A1 (en) * | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
US20050152884A1 (en) * | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
US20050158294A1 (en) * | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US8894991B2 (en) * | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
ES2253091B1 (es) * | 2004-07-27 | 2007-02-01 | Inke, S.A. | Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo. |
EP1838716B1 (en) | 2005-01-05 | 2011-06-01 | Eli Lilly And Company | Olanzapine pamoate dihydrate |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP2008536922A (ja) * | 2005-04-22 | 2008-09-11 | テバ・ファーマシューティカルズ・ユーエスエー・インコーポレイテッド | オランザピンの医薬用経口崩壊錠 |
WO2006130187A1 (en) * | 2005-05-31 | 2006-12-07 | The Iams Company | Feline probiotic lactobacilli |
BRPI0611492B1 (pt) * | 2005-05-31 | 2021-10-13 | Mars, Incorporated | Bifidobactéria probiótica felina |
US20070014847A1 (en) * | 2005-07-05 | 2007-01-18 | Ahmed Salah U | Coated capsules and methods of making and using the same |
WO2007014124A2 (en) * | 2005-07-22 | 2007-02-01 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
WO2007049304A2 (en) * | 2005-10-27 | 2007-05-03 | Jubilant Organosys Limited | Stable coated pharmaceutical formulation of olanzapine and process for preparing the same |
GB0522473D0 (en) * | 2005-11-03 | 2005-12-14 | Actavis Group | A pharmaceutical formulation |
GB0522474D0 (en) | 2005-11-03 | 2005-12-14 | Actavis Group | A pharmaceutical formulation |
ES2279715B1 (es) * | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
US7834176B2 (en) | 2006-01-26 | 2010-11-16 | Sandoz Ag | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E |
US20070293479A1 (en) * | 2006-05-18 | 2007-12-20 | Osinga Niels J | Olanzapine pharmaceutical composition |
EP2043612B1 (en) * | 2006-07-05 | 2010-04-28 | Bilim Ilac Sanayii Ve Ticaret A.S. | A stable olanzapine formulation with antioxidants |
CL2007002807A1 (es) * | 2006-09-29 | 2008-04-11 | Synthon Bv | Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren |
CN101711158A (zh) | 2007-02-01 | 2010-05-19 | 爱默思公司 | 使用葡萄糖抗代谢物、鳄梨或鳄梨提取物减轻哺乳动物炎症和应激反应的方法 |
JP4656672B2 (ja) * | 2008-01-31 | 2011-03-23 | 杏林製薬株式会社 | イミダフェナシンを有効成分とする口腔内速崩錠の製造方法 |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
KR20120093060A (ko) * | 2009-03-25 | 2012-08-22 | 카이틴, 아이엔씨. | 초음파 냉각 시스템 |
US20110048048A1 (en) * | 2009-03-25 | 2011-03-03 | Thomas Gielda | Personal Cooling System |
US8505322B2 (en) * | 2009-03-25 | 2013-08-13 | Pax Scientific, Inc. | Battery cooling |
US20110051549A1 (en) * | 2009-07-25 | 2011-03-03 | Kristian Debus | Nucleation Ring for a Central Insert |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
US8365540B2 (en) * | 2009-09-04 | 2013-02-05 | Pax Scientific, Inc. | System and method for heat transfer |
WO2012153347A2 (en) | 2011-05-04 | 2012-11-15 | Zentiva K.S. | Oral pharmaceutical composition of olanzapine form 1 |
EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA |
US9517212B1 (en) * | 2012-11-15 | 2016-12-13 | Chandra Zaveri | Medicated adhesive pad arrangement |
CN103919782B (zh) * | 2013-01-15 | 2016-12-28 | 天津药物研究院有限公司 | 一种含有奥氮平的药物组合物及其制备方法 |
DK3043778T3 (da) * | 2013-09-13 | 2017-11-27 | Bayer Pharma AG | Farmaceutiske sammensætninger, der indeholder refametinib |
CN107007559B (zh) * | 2017-04-21 | 2020-05-15 | 浙江京新药业股份有限公司 | 一种稳定的口服药物组合物及其制备方法 |
AU2018275686B2 (en) * | 2017-06-02 | 2024-02-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
CN113143878A (zh) * | 2021-03-19 | 2021-07-23 | 杭州新诺华医药有限公司 | 奥氮平组合物及其制备方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4172831A (en) * | 1974-11-26 | 1979-10-30 | Lilly Industries Limited | Thieno-benzodiazepines |
US4115568A (en) * | 1974-11-26 | 1978-09-19 | Lilly Industries Limited | Thieno[3,2-b]-[1,5]benzodiazepines |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
US4820522A (en) * | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
ZA922776B (en) * | 1991-04-29 | 1993-10-15 | Lilly Co Eli | Pharmaceutical compounds |
JPH05194225A (ja) * | 1991-11-07 | 1993-08-03 | Yoshitomi Pharmaceut Ind Ltd | 安定化された抗潰瘍剤含有製剤 |
PT582368E (pt) * | 1992-05-29 | 2001-05-31 | Lilly Co Eli | Derivados de tienobenzodiazepina para o tratamento de doencas de cns |
SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
CR5278A (es) * | 1995-03-24 | 1996-07-04 | Lilly Co Eli | Formulacion oral de 2-metil-tieno-benzodiacepina |
US5696115A (en) * | 1995-04-21 | 1997-12-09 | Eli Lilly And Company | Method for treating nicotine withdrawal |
-
1996
- 1996-03-12 CR CR5278A patent/CR5278A/es not_active Application Discontinuation
- 1996-03-21 EG EG25196A patent/EG24077A/xx active
- 1996-03-22 PL PL96322579A patent/PL188316B1/pl unknown
- 1996-03-22 EA EA199700260A patent/EA000938B1/ru not_active IP Right Cessation
- 1996-03-22 CA CA002216372A patent/CA2216372C/en not_active Expired - Lifetime
- 1996-03-22 AT AT96301997T patent/ATE206924T1/de active
- 1996-03-22 AT AT0902296A patent/AT405606B/de not_active IP Right Cessation
- 1996-03-22 TW TW085103453A patent/TW426526B/zh not_active IP Right Cessation
- 1996-03-22 CZ CZ19973001A patent/CZ296007B6/cs not_active IP Right Cessation
- 1996-03-22 EP EP00204708A patent/EP1093815B1/en not_active Expired - Lifetime
- 1996-03-22 DE DE19681287T patent/DE19681287T1/de not_active Ceased
- 1996-03-22 CO CO96014566A patent/CO4700474A1/es unknown
- 1996-03-22 PT PT00204708T patent/PT1093815E/pt unknown
- 1996-03-22 DK DK00204708T patent/DK1093815T3/da active
- 1996-03-22 SI SI9620041A patent/SI9620041A/sl unknown
- 1996-03-22 RO RO97-01776A patent/RO118370B1/ro unknown
- 1996-03-22 AR AR33587496A patent/AR001405A1/es not_active Application Discontinuation
- 1996-03-22 DK DK96301997T patent/DK0733367T3/da active
- 1996-03-22 CH CH02246/97A patent/CH691217A5/de not_active IP Right Cessation
- 1996-03-22 MY MYPI96001086A patent/MY113440A/en unknown
- 1996-03-22 HU HU9800410A patent/HU225269B1/hu unknown
- 1996-03-22 JP JP8529533A patent/JPH11502848A/ja active Pending
- 1996-03-22 NZ NZ306111A patent/NZ306111A/xx not_active IP Right Cessation
- 1996-03-22 ES ES00204708T patent/ES2232379T3/es not_active Expired - Lifetime
- 1996-03-22 BR BR9607791A patent/BR9607791A/pt not_active IP Right Cessation
- 1996-03-22 PE PE1996000204A patent/PE44997A1/es not_active IP Right Cessation
- 1996-03-22 GB GB9719817A patent/GB2313783B/en not_active Revoked
- 1996-03-22 EE EE9700328A patent/EE03551B1/xx unknown
- 1996-03-22 AR ARP960101877A patent/AR002720A1/es not_active Application Discontinuation
- 1996-03-22 SI SI9630707T patent/SI1093815T1/xx unknown
- 1996-03-22 AP APAP/P/1997/001064A patent/AP679A/en active
- 1996-03-22 AU AU54280/96A patent/AU696601B2/en not_active Ceased
- 1996-03-22 UA UA97094738A patent/UA44766C2/uk unknown
- 1996-03-22 WO PCT/US1996/003918 patent/WO1996029995A1/en active IP Right Grant
- 1996-03-22 ZA ZA9602338A patent/ZA962338B/xx unknown
- 1996-03-22 SI SI9630404T patent/SI0733367T1/xx unknown
- 1996-03-22 IL IL11761196A patent/IL117611A/en unknown
- 1996-03-22 PT PT96301997T patent/PT733367E/pt unknown
- 1996-03-22 EP EP96301997A patent/EP0733367B1/en not_active Expired - Lifetime
- 1996-03-22 KR KR1019970706592A patent/KR100408172B1/ko not_active IP Right Cessation
- 1996-03-22 SK SK1282-97A patent/SK283745B6/sk not_active IP Right Cessation
- 1996-03-22 CN CNB96192778XA patent/CN1178662C/zh not_active Expired - Fee Related
- 1996-03-22 AT AT00204708T patent/ATE284695T1/de active
- 1996-03-22 TR TR97/01018T patent/TR199701018T1/xx unknown
- 1996-03-22 DE DE69634053T patent/DE69634053T2/de not_active Expired - Lifetime
- 1996-03-22 DE DE69615887T patent/DE69615887T2/de not_active Expired - Lifetime
- 1996-03-22 ES ES96301997T patent/ES2164837T3/es not_active Expired - Lifetime
- 1996-09-20 US US08/716,922 patent/US5919485A/en not_active Expired - Lifetime
-
1997
- 1997-07-30 LU LU90115A patent/LU90115B1/fr active
- 1997-09-05 SE SE9703206A patent/SE9703206D0/xx not_active Application Discontinuation
- 1997-09-16 LT LT97-149A patent/LT4350B/lt not_active IP Right Cessation
- 1997-09-22 IS IS4565A patent/IS1903B/is unknown
- 1997-09-22 BG BG101901A patent/BG62594B1/bg unknown
- 1997-09-22 FI FI973749A patent/FI973749A/fi unknown
- 1997-09-22 NO NO19974363A patent/NO320388B1/no not_active IP Right Cessation
- 1997-09-23 DK DK199701090A patent/DK173323B1/da not_active IP Right Cessation
- 1997-09-24 OA OA70083A patent/OA10511A/en unknown
- 1997-10-14 LV LVP-97-199A patent/LV11983B/en unknown
-
1998
- 1998-08-31 US US09/144,188 patent/US6190698B1/en not_active Expired - Lifetime
-
2001
- 2001-01-19 US US09/766,218 patent/US6780433B2/en not_active Expired - Fee Related
-
2004
- 2004-07-08 US US10/887,017 patent/US7229643B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE44997A1 (es) | Formulacion oral de 2-metil-tieno-benzodiacepina (olanzapina) y procedimiento de preparacion | |
GR880100258A (en) | Preparation method of a mould for the retarded liberating of impuprofene | |
CA2654493C (en) | Tablet comprising candesartan cilexetil | |
ES2083074T3 (es) | Dispositivo de liberacion controlada. | |
HK1049797A1 (en) | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations | |
BR9811789A (pt) | Artigo de limpeza e condicionamento para tratamento pessoal de utilização única, descartável e processos para manufaturar esse artigo e para limpar e condicionar a pele ou cabelo com esse artigo | |
AR049057A2 (es) | Una tableta rapidamente desintegrable para la administracion por via oral | |
RU94028273A (ru) | Фармацевтические композиции, обладающие хорошей растворимостью, способ ее сохранения и улучшения | |
UY23240A1 (es) | Procedimiento para la preparacion de una composicion farmaceutica inyectable | |
DE58901990D1 (de) | Feste pharmazeutische retardform. | |
KR920019340A (ko) | 최적화된 정제 제제 | |
PE27899A1 (es) | Formulacion de particulas revestidas | |
ES2175073T3 (es) | Procedimiento de preparacion de formas para la administracion oral de antibioticos beta-lactamicos de rapida dispersabilidad en agua. | |
KR20010062478A (ko) | 경구투여후 트리메트아지딘의 지속적 방출을 가능케 하는매트릭스 정제 | |
RU2311906C2 (ru) | Композиция препарата замедленного высвобождения для высвобождения ингибитора секреции кислоты в желудке и способ ее получения | |
PE20000329A1 (es) | Derivados de indol y composiciones farmaceuticas que los contienen | |
NO178338C (no) | Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse samt mellomprodukt | |
ES2090490T3 (es) | Supositorios de liberacion prolongada y un procedimiento para su preparacion. | |
ES2043722T3 (es) | Formulacion oral de teofilina de liberacion sostenida en seco y mejorada. | |
RU2004122479A (ru) | Содержащая свехчистую флудару пероральная композиция с быстрым высвобождением действующего вещества | |
CA2020590A1 (en) | Solid pharmaceutical composition containing a core and an outer layer | |
RU2002120346A (ru) | Ферментный препарат "панзим форте" | |
KR950031064A (ko) | 젬피브로질 함유 약제학적 조성물 | |
WO1991001714A1 (en) | Ophthalmic composition | |
AR003631A4 (es) | Corona floral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
MC | Annulment |